A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Status:	Recruiting
Conditions:	Colitis, Colitis, Gastrointestinal
Therapuetic Areas:	Gastroenterology
Healthy:	No
Age Range:	18 - 80
Updated:	4/5/2019
Start Date:	July 18, 2018
End Date:	August 23, 2023
Contact:	There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Email:	ClinicalTrials.gov@lilly.com
Phone:	1-317-615-4559

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3

This study designed to evaluate the long-term efficacy and safety of mirikizumab in
participants with moderately to severely active ulcerative colitis (UC).

- Inclusion Criteria

- Participants from Study AMAC (NCT02589665) or AMBG (NCT #:TBD) who have had at
least one study drug administration and have not had early termination of study
drug.

- Female participants must agree to contraception requirements.

- Exclusion Criteria

- Participants must not have developed a new condition, including cancer in the
originator study.

- Participants must not have any important infections including, but not limited
to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during
either originator study

- Participants may not have received surgery for UC in the originator study or are
likely to require surgery for treatment of UC during the study.

- Participants must not have developed adenomatous polyps during the originator
study that have not been removed prior to the start of this study.

We found this trial at

sites

Borland-Groover Clinic

4800 Belfort Rd # 2
Jacksonville, Florida 32256

Principal Investigator: Mark R Fleisher

Phone: 904-398-3262

from

Jacksonville, FL